Drugs.com - New Drug Approvals

Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle Cell Lymphoma

17 January 2025 -- AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible...

Feb 9, 2025 - 22:25
 0
Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle Cell Lymphoma
17 January 2025 -- AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible...
Read More

Tags:

Previous Article

FDA Approves Datroway (datopotamab deruxtecan-dlnk) for Patients with Previously...

Next Article

FDA Approves Lumakras (sotorasib) in Combination with Vectibix (panitumumab) for...

Related Posts

Sumitomo Pharma America Announces U.S. FDA Approval of Gemtesa (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Sumitomo Pharma America Announces U.S. FDA Approval of ...

Feb 9, 2025  0

FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA to Reduce the Risk of Worsening Kidney Disease and Cardiovascular Death in Adults with Type 2 Diabetes and Chronic Kidney Disease

FDA Approves Ozempic (semaglutide) as the Only GLP-1 RA...

Feb 9, 2025  0

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

FDA Approves Xbryk (denosumab-dssb), a Biosimilar to Xgeva

Feb 17, 2025  0